期刊文献+

罗沙司他药物利用评价标准的建立与应用

Establishment and application of drug use evaluation criteria for roxadustat
在线阅读 下载PDF
导出
摘要 目的 建立罗沙司他药物利用评价(DUE)标准,评价罗沙司他的临床应用情况,促进该药的合理使用。方法 基于罗沙司他药品说明书,参考相关指南、专家共识,通过德尔菲法建立罗沙司他DUE标准,包括用药指征、用药过程和用药结果等项目。采用回顾性研究方法,对福建省立医院2020年1月1日—2022年12月31日首次使用罗沙司他且用药周期> 1个月的住院患者病历进行用药合理性评价。结果 共纳入175份病历,其中临床应用完全符合评价标准的有14例,用药合理率为8.0%。不合理问题主要为临床结局不适宜(92.0%)、给药剂量不适宜(52.6%)、不良反应监护不适宜(34.9%)、给药时机不适宜(13.1%)、存在药物相互作用(8.7%)、药物转化不适宜(5.7%)、疗效监护不适宜(4.0%)。结论 建立的罗沙司他药物评价标准科学、实用、可行,评价结果显示该院罗沙司他在使用过程中不合理率较高,需在用法用量、不良反应监护、给药时机等方面规范罗沙司他的使用。 Objective To establish the drug use evaluation(DUE)standards of roxadustat,and to evaluate its clinical application to promote its rational use.Methods Based on the drug labels,referring to relevant guidelines and expert consensus,the DUE criteria for roxadustat were established through the Delphi method,including items such as drug indications,drug use process and the results of medication.A retrospective study was conducted to evaluate the rationality of cases which included inpatients who used roxadustat for the first time from January 1,2020 to December 31,2022,with a medication period of more than one month in Fujian Provincial Hospital.Results A total of 175 medical records were included,of which 14 records were fully met the clinical application evaluation criteria,and the medication reasonable rate was 8.0%.The unreasonable situation were mainly manifested in the inappropriate clinical outcomes(92.0%),the inappropriate use dosages(52.6%),inappropriate monitoring of adverse reactions(34.9%),inappropriate timing of administration(13.1%),drug interactions(8.7%),inappropriate drug conversion(5.7%),inappropriate efficacy monitoring(4.0%).Conclusion The established DUE standards for roxadustat are scientific,practical and feasible,and the evaluation results show a rate of irrationality in the use of roxadustat in the hospital,and it is necessary to standardize the use of roxadustat in terms of dosage,adverse reaction monitoring,and timing of administration.
作者 黄玲芳 洪珊珊 张进华 黄旭慧 HUANG Lingfang;HONG Shanshan;ZHANG Jinhua;HUANG Xuhui(Department of Pharmacy,Fujian Provincial Hospital,Fuzhou 350001,China;Department of Pharmacy,Quanzhou First Hospital of Fujian Province,Quanzhou 362000,Fujian Province,China;Department of Pharmacy,Fujian Maternity and Child Health Hospital,Fuzhou 350001,China)
出处 《药物流行病学杂志》 CAS 2024年第2期128-136,共9页 Chinese Journal of Pharmacoepidemiology
基金 福建医科大学启航基金一般项目(2021QH1310)。
关键词 罗沙司他 药物利用评价 德尔菲法 合理用药 Roxadustat Drug utilization evaluation Delphi method Rational drug use
作者简介 通信作者:黄旭慧,主任药师,Email:huangys1024@163.com;通信作者:张进华,博士,主任药师,硕士研究生导师,Email:pollyzhang2006@126.com。
  • 相关文献

参考文献10

二级参考文献81

  • 1赖世隆.方药临床试验观测的可靠性分析[J].中药新药与临床药理,1991,2(1):51-55. 被引量:2
  • 2李家泰.临床毒理学与药物评价[J].中国临床药理学杂志,1994,10(3):184-188. 被引量:37
  • 3胡大清 熊方武.评估可疑药物不良反应“循序辩证法”[J].药物流行病学杂志,1993,2(1):44-44.
  • 4李性天 瞿明霞.特异性药物不良反应的贝叶斯鉴别诊断方法[J].药物流行病学杂志,1993,2(3):148-148.
  • 5陈香美,孙雪峰,蔡广研.重组人促红细胞生成素在肾性贫血中合理应用的专家共识[J].中国血液净化,2007,6(8):440-443. 被引量:112
  • 6McClellan WM, Flanders WD, Gutman RA. Variable mortality rates among dialysis treatment centers. Ann Intern Med 1992; 117: 332-336.
  • 7Hall YN, Jolly SE, Xu R Abrass CK, Buchwald D, Himmelfarb J. Regional differences in dialysis care and mortality among American Indians and Alaska Natives. J Am Soc Nephrol 2011; 22: 2287-2295.
  • 8Lopes AA, Bragg-Gresham JL, Goodkin DA, Fukuhara S, Mapes DL, Young EW, et al. Factors associated with health-related quality of life among hemodialysis patients in the DOPPS. Qual Life Res 2007; 16: 545-557.
  • 9Goodkin DA, Mapes DL, Held PJ. The dialysis outcomes and practice patterns study (DOPPS): how can we improve the care of hemodialysis patients? Sernin Dial 2001; 14:157-159.
  • 10Tentori F. Trends in medication use and clinical outcomes in twelve countries: results from the dialysis outcomes and practice patterns study (DOPPS). Contrib Nephrol 2008; 161: 48-54.

共引文献443

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部